elantiva glp-1 Stopping Receptor Agonists… Why and How to Plan an “Exit Strategy” for Your Patients elénzia CONTROL® | Natural GLP-1

Together, they discuss drug quality, patient safety, and how advocacy can help drive meaningful change in the healthcare system

Refusal to obtain recommended laboratory testing may result in provider inability to continue prescribing compounded GLP-1 medications due to safety concerns and inability to monitor for potential complications

Along with lifestyle changes, these therapies help manage diabetes and obesity by: Helping the body release insulin which moves sugar from the blood to the cells to be used for energy Stopping blood sugar spikes by reducing the release of a hormone that raises blood sugar Slowing digestion so people feel full longer and are less likely to overeat Though GLP-1 agonists were first approved by the FDA in 2005, they are still being studied

The current patent system allows companies to develop patent thickets by making minor modifications to an existing drug, which then allows them to extend their patent protection and increase the possibility of lengthening their market monopoly

[DOI] [PMC free article] [PubMed] [Google Scholar] 137.Seminer A, et al

A major clinical trial showed patients taking oral semaglutide lost approximately 35% of their body weight over 26 weeks, with some individuals achieving greater reductions through consistent diet and exercise adherence